Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized Trials

摘要: Purpose: The logic behind the application of luteinizing hormone-releasing hormone (LHRH) agonists in combination with tamoxifen premenopausal women is that LHRH on one hand suppress tamoxifen-induced stimulation pituitary-ovarian function and, other hand, seem as effective surgical castration. This meta-analysis combines all randomized evidence to compare combined treatment agonist alone respect overall survival, progression-free and objective response advanced breast cancer. Patients Methods: Four clinical trials randomising a total 506 cancer or plus were identified. Meta-analytic techniques used analyze individual patient data from these trials. Results: With median follow-vp 6.8 years, there was significant survival benefit (stratified log-rank test, P =.02; hazards ratio [HR] = 0.78) =.0003; HR 0.70) favor treatment. rate significantly higher endocrine Mantel Haenszel =.03; odds 0.67). Conclusion: superior Therefore, if woman thought be suitable for it proposed considered new standard J Clin Oncol 19:343-353. (C) 2001 by American Society Clinical Oncology.